Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
暂无分享，去创建一个
K. Azuma | H. Kenmotsu | Toshiaki Takahashi | N. Yamamoto | R. Toyozawa | K. Nakagawa | S. Sugawara | H. Hayashi | K. Mori | S. Miura | T. Kato | T. Shukuya | D. Fujimoto | K. Wakuda | Y. Yoneshima | K. Masuda | K. Nishino | S. Teraoka | K. Kirita